Biodexa Pharmaceuticals PLC ADR (BDRX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
BDRX Chart
Shareholder Update
May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced a brief update for shareholders. Financial position As of May 29, 2025, the Company had access to the following cash resources: $ millions Cash at bank 5.7 Cash in escrow for eRapa Phase 3 program 4.4 10.1 Undrawn CPRIT grant for eRapa Phase 3 program 11.9 Debt 0.5 The CPRIT grant, together with Company match means the eRapa Phase 3 program is substantially funded.
Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M
May 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced its collaboration partner, Rapamycin Holdings, Inc. d/b/a Emtora Biosciences (“Emtora”) has been awarded an additional grant of $3.0 million from the Cancer Prevention & Research Institute of Texas (“CPRIT”). This award brings the total grant awarded by CPRIT to support the registrational Phase 3 program of eRapa in familial adenomatous polyposis (“FAP”) to $20.0 million.
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears start of Registrational Phase 3 study targeted at an addressable market of $7.3Bn Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the European Commission (EC) has granted Orphan Drug Designation for eRapa in familial adenomatous polyposis (FAP), a largely inherited precancerous disease of the colon for which there is currently no pharmaceutical intervention. ” This Orphan Drug Designation is another important step as we move our FAP program forward into a registrational Phase 3 study.
Biodexa Pharmaceuticals PLC ADR Dividends
Biodexa Pharmaceuticals PLC ADR Earnings
Biodexa Pharmaceuticals PLC ADR (BDRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biodexa Pharmaceuticals PLC ADR ever had a stock split?
Biodexa Pharmaceuticals PLC ADR Profile
| Biotechnology Industry | Healthcare Sector | Mr. Stephen Anthony Stamp CEO | NASDAQ (CM) Exchange | 59564R807 Cusip |
| GB Country | 13 Employees | - Last Dividend | 4 Oct 2024 Last Split | - IPO Date |
Overview
Biodexa Pharmaceuticals Plc is a clinical stage biopharmaceutical company dedicated to developing innovative solutions for Type 1 diabetes and rare/orphan brain cancers. Originating in 2000 and formerly known as Midatech Pharma plc until its rebranding in March 2023, the company is strategically based in Cardiff, the United Kingdom. Biodexa Pharmaceuticals Plc aims to advance the medical field with its cutting-edge research and developmental efforts, focusing on creating effective treatments that address the unmet needs in these challenging medical conditions.
Products and Services
-
Tolimidone
As Biodexa Pharmaceuticals Plc's lead product candidate, Tolimidone is a groundbreaking selective activator of the lyn kinase enzyme. It is currently under Phase II studies for its potential to treat Type 1 diabetes, exemplifying the company’s commitment to combating this chronic condition with innovative therapeutic methods.
-
MTX110
MTX110 represents a significant part of Biodexa Pharmaceuticals' pipeline, currently in Phase I studies targeting diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. This highlights the company's dedication to addressing some of the most challenging and rare cancer types with novel treatment options.
-
MTD217
This program revolves around MTD217, a water-soluble drug formulation designed for easy infusion or injection directly into the cancer microenvironment. Currently under preclinical studies for the treatment of leptomeningeal disease, MTD217 aims to offer a novel approach to challenging cancer treatments through targeted therapy.
-
Drug Delivery Platforms
Q-Sphera: A polymer microsphere microtechnology intended for sustained release drug delivery, showcasing Biodexa Pharmaceuticals' focus on innovative drug delivery solutions.
MidaSolve: An oligosaccharide nanotechnology designed to solubilize drugs for direct, local administration into tumors in liquid form, further exemplifying the company's innovative approach to cancer treatment.
MidaCore: Utilizes gold nanoparticles for disease site targeting, using chemotherapeutic or immunotherapeutic agents, highlighting the company’s investment in nanotechnology for precise and effective cancer therapy.
Contact Information
